- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07626411
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Studiesteder
-
-
-
Longueuil, Canada, J4H4B9
- Rekruttering
- Viacar Recherches Cliniques inc.
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G4
- Rekruttering
- Premiere Clinical Trial Network
-
Scarborough Village, Ontario, Canada, M1B 4Z8
- Rekruttering
- Heart Health Institute Research Inc.
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1LOK3
- Rekruttering
- Diex Recherche Inc.
-
-
-
-
Alabama
-
Alexander City, Alabama, Forente stater, 35010
- Rekruttering
- Advanced Cardiovascular
-
Dothan, Alabama, Forente stater, 36305
- Rekruttering
- SEC Clinical Research
-
Fairhope, Alabama, Forente stater, 36532
- Rekruttering
- Eastern Shore Research Institute
-
-
Arizona
-
Glendale, Arizona, Forente stater, 85306
- Rekruttering
- West Valley Clinical Trials
-
Scottsdale, Arizona, Forente stater, 85260
- Rekruttering
- Scottsdale Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Rekruttering
- Arkansas Cardiology P.A.
-
-
California
-
Covina, California, Forente stater, 91723
- Rekruttering
- Valley Clinical Trials, Inc
-
Fremont, California, Forente stater, 94538
- Rekruttering
- Mission Cardiovascular Research Institute
-
Huntington Beach, California, Forente stater, 92648
- Rekruttering
- National Institute of California Heart and Vein Specialists
-
Inglewood, California, Forente stater, 90301
- Rekruttering
- Alliance Clinical Los Angeles
-
La Jolla, California, Forente stater, 92037
- Rekruttering
- Profound Research LLC at San Diego Cardiovascular Associates
-
Newport Beach, California, Forente stater, 92663
- Rekruttering
- Radin Cardiovascular Medical Group
-
Northridge, California, Forente stater, 91325
- Rekruttering
- Valley Clinical Trials, LLC dba Flourish Research
-
Pasadena, California, Forente stater, 91105
- Rekruttering
- Southern California Heart Specialists
-
Redding, California, Forente stater, 96001
- Rekruttering
- The Cardiovascular Center
-
Santa Maria, California, Forente stater, 93454
- Rekruttering
- FOMAT - Comprehensive Cardiovascular Care
-
Ventura, California, Forente stater, 93003
- Rekruttering
- Cardiology Associates Medical Group
-
West Hills, California, Forente stater, 91307
- Rekruttering
- Interventional Cardiology Medical Group
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33434
- Rekruttering
- Excel Medical Clinical Trials, dba Flourish Research
-
Cutler Bay, Florida, Forente stater, 33189
- Rekruttering
- Nouvelle Clinical Research LLC
-
Inverness, Florida, Forente stater, 34452
- Rekruttering
- Nature Coast Clinical Research - Inverness
-
Jacksonville, Florida, Forente stater, 32216
- Rekruttering
- East Coast Institute for Research, Jacksonville
-
Medley, Florida, Forente stater, 33166
- Rekruttering
- South Florida Research Organization LLC
-
Miami, Florida, Forente stater, 33135
- Rekruttering
- Novera Clinical Research
-
New Smyrna Beach, Florida, Forente stater, 32168
- Rekruttering
- Healix Clinical Research
-
Pensacola, Florida, Forente stater, 32503
- Rekruttering
- Sec Clinical Research
-
Saint Augustine, Florida, Forente stater, 32086
- Rekruttering
- Flourish Research, St. Johns Center for Clinical Research
-
Saint Augustine, Florida, Forente stater, 32086
- Rekruttering
- East Coast Institute for Research, St. Augustine
-
Sarasota, Florida, Forente stater, 34239
- Rekruttering
- Cardiovascular Center of Sarasota Foundation for Research and Education
-
Winter Park, Florida, Forente stater, 32789
- Rekruttering
- Clinical Site Partners, LLC DBA Flourish Research
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Rekruttering
- Atlanta Clinical Research Centers
-
Atlanta, Georgia, Forente stater, 30310
- Rekruttering
- Morehouse School Of Medicine
-
Johns Creek, Georgia, Forente stater, 30024
- Rekruttering
- NSC Research, Inc
-
-
Indiana
-
Hobart, Indiana, Forente stater, 46342
- Rekruttering
- Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
-
Indianapolis, Indiana, Forente stater, 46237
- Rekruttering
- Franciscan Physician Network, Indiana Heart Physicians
-
Munster, Indiana, Forente stater, 46321
- Rekruttering
- Profound Research, Powers Health Medical Group - Electrophysiology
-
Munster, Indiana, Forente stater, 46321-4054
- Rekruttering
- Cardiovascular Research of Northwest Indiana, LLC
-
-
Louisiana
-
West Monroe, Louisiana, Forente stater, 71291
- Rekruttering
- Monroe Research, LLC
-
-
Maryland
-
Ft. Washington, Maryland, Forente stater, 20744
- Rekruttering
- Anderson Medical Research
-
-
Massachusetts
-
Foxborough, Massachusetts, Forente stater, 02035
- Rekruttering
- K2 Medical Research, Foxboro
-
-
Michigan
-
Bloomfield Hills, Michigan, Forente stater, 48304
- Rekruttering
- Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
-
Farmington Hills, Michigan, Forente stater, 48334
- Rekruttering
- Profound Research, Millennium Cardiology
-
Flint, Michigan, Forente stater, 48503
- Rekruttering
- Flint Clinical Research
-
Flint, Michigan, Forente stater, 48504
- Rekruttering
- AA Medical Research Center (MRC)
-
-
New York
-
Staten Island, New York, Forente stater, 10309
- Rekruttering
- Super Health Pharmacy
-
-
North Carolina
-
Concord, North Carolina, Forente stater, 28025
- Rekruttering
- Hawthorne Health, Moose Pharmacy of Concord
-
High Point, North Carolina, Forente stater, 27260
- Rekruttering
- Peters Medical Research
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58104
- Rekruttering
- Lillestol Research LLC
-
-
Ohio
-
Marion, Ohio, Forente stater, 43302
- Rekruttering
- K&R Research LLC
-
Maumee, Ohio, Forente stater, 43537
- Rekruttering
- Advanced Medical Research
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57701
- Rekruttering
- Monument Health Clinical Research
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37912
- Rekruttering
- Norwood Family Medicine
-
Tullahoma, Tennessee, Forente stater, 37388
- Rekruttering
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
- Rekruttering
- PharmaTex Research
-
Brownsville, Texas, Forente stater, 78520
- Rekruttering
- PanAmerican Clinical Research
-
Houston, Texas, Forente stater, 77061
- Rekruttering
- Synergy Groups Medical
-
Houston, Texas, Forente stater, 77094
- Rekruttering
- West Houston Area Clinical Trial Consultants, LLC
-
Houston, Texas, Forente stater, 77036
- Rekruttering
- Synergy Group Medical
-
McKinney, Texas, Forente stater, 75071
- Rekruttering
- Texas Institute of Cardiology PA
-
Missouri City, Texas, Forente stater, 77459
- Rekruttering
- Synergy Group Medical, LLC
-
Odessa, Texas, Forente stater, 79761
- Rekruttering
- Permian Research Foundation
-
Tyler, Texas, Forente stater, 75701
- Rekruttering
- Tyler Cardiovascular Consultants
-
-
Utah
-
Clinton, Utah, Forente stater, 84015
- Rekruttering
- Alpine Research TC
-
Provo, Utah, Forente stater, 84604
- Rekruttering
- Boeson Research PVU
-
-
Virginia
-
Manassas, Virginia, Forente stater, 20109
- Rekruttering
- Carient Heart & Vascular
-
Vienna, Virginia, Forente stater, 22182
- Rekruttering
- Conquest Research
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 466-8650
- Rekruttering
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
-
-
Ehime
-
Uwajima, Ehime, Japan, 798-8510
- Rekruttering
- Uwajima City Hospital
-
-
Fukuoka
-
Onga District, Fukuoka, Japan, 811-4342
- Rekruttering
- Onga Nakama Medical Association Onga Hospital
-
-
Gifu
-
Gifu, Gifu, Japan, 500-8717
- Rekruttering
- Gifu Prefectural General Medical Center - Main Hospital Building
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 062-0003
- Rekruttering
- Hanaoka Seishu Memorial Hospital
-
-
Hyōgo
-
Kawanishi, Hyōgo, Japan, 666-0125
- Rekruttering
- The Veritas Hospital
-
-
Ibaraki
-
Higashiibaraki District, Ibaraki, Japan, 311-3193
- Rekruttering
- National Hospital Organization Mito Medical Center
-
Tsuchiura, Ibaraki, Japan, 300-8585
- Rekruttering
- National Hospital Organization Kasumigaura Medical Center
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 234-0054
- Rekruttering
- Saiseikai Yokohama-shi Nanbu Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 607-8062
- Rekruttering
- Rakuwakai Otowa Hospital
-
-
Shizuoka
-
Shizuoka, Shizuoka, Japan, 420-8630
- Rekruttering
- Shizuoka City Shizuoka Hospital, East Building
-
-
Tokyo
-
Hachiōji, Tokyo, Japan, 192-0918
- Rekruttering
- Minamino Cardiovascular Hospital
-
Suginami Ward, Tokyo, Japan, 168-0065
- Rekruttering
- NewHeart Watanabe International Hospital
-
-
Yokohama-shi
-
Kanagawa, Yokohama-shi, Japan, 247-0005
- Rekruttering
- JA Tsuchiura Kyodo General Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
-
Meets one of the following:
- CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
- CHA2DS2-VA score ≥3 OR
- CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
-
Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)
Key Exclusion Criteria:
- Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
- Has known moderate-to-severe mitral stenosis
- Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
- Had an ischemic stroke within 2 days prior to randomization
- Has persistent, uncontrolled hypertension (per investigator's discretion)
- Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: REGN7508 + Placebo
|
Administered per the protocol Administered per the protocol
Andre navn:
|
|
Aktiv komparator: Apixaban + Placebo
|
Administered per the protocol Administered per the protocol |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of ISTH major bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to occurrence of fatal bleeding
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH major bleeding events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH CRNM bleeding events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Number of minor bleeding events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Time to all-cause death
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Approximately 39 months
|
Approximately 39 months
|
|
Severity of TEAEs
Tidsramme: Approximately 39 months
|
Approximately 39 months
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Magnitude of ADA to REGN7508
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Arytmier, hjerte
- Embolisme og trombose
- Patologiske tilstander, tegn og symptomer
- Slag
- Trombose
- Atrieflimmer
- Blødning
- Apixaban
Andre studie-ID-numre
- R7508-CVA-24114
- 2025-521617-97-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Tilgangskriterier for IPD-deling
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .